Weekly Roundup: Navigating Life Sciences Week- The Official Guide Is Live 🚨
R1 Therapeutics to present Phase 2b trial-in-progress poster for AP306 at ASN Kidney Week 2026
R1 Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class therapies for patients with kidney disease, announced the presentation of a trial-in-progress poster highlighting its ongoing global Phase 2b study of AP306 at the American Society of Nephrology (ASN) Kidney Week 2026, taking place October 21–25, 2026, in Denver, Colorado.
iOnctura appoints Paul Sekhri as Chair of its Board of Directors
iOnctura, a clinical-stage precision oncology company combating neglected and hard-to-treat cancers, announced the appointment of Paul Sekhri as Chair of its Board of Directors with immediate effect. Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercialization. His appointment comes as iOnctura prepares for late-stage development of roginolisib, with two randomized studies (in uveal melanoma and lung cancer) fully enrolled.
Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of potential disease-modifying treatment MTX325
Mission Therapeutics Limited, a clinical-stage biotechnology company discovering and developing novel therapeutics to restore cellular health and function by promoting the removal of dysfunctional mitochondria, announced the first patient has been dosed in its Phase 1b proof-of-mechanism study of MTX325 in patients with Parkinson’s disease (PD). The patient was dosed at the Royal Liverpool University Hospital in the UK.
Â
DaltonTx awarded grant to accelerate AI-powered tuberculosis drug discovery
DaltonTx, the decision engine for drug discovery, announced that it has been awarded a grant by the Gates Foundation to advance tuberculosis (TB) drug discovery programmes using its AI-enabled platform, Dalton. Funding from the Gates Foundation supports development of open-access AI models, workflows and datasets to help researchers identify new tuberculosis (TB) targets for faster and more cost-effective drug discovery.
Â
Sapreme Therapeutics announces oral presentation of new preclinical data on lead Duchenne muscular dystrophy candidate SPM-2551 at OTS 2026
Sapreme Therapeutics, a biotechnology company developing next-generation RNA therapeutics for patients with genetically driven diseases, on Wednesday revealed new preclinical data from its lead Duchenne muscular dystrophy (DMD) programme, SPM-2551, in an oral presentation at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), Â which took place in Denver, Colorado, US.
Â
Hansa Biopharma participated in fireside chat at virtual US Bancorp / BTIG Kidney Health Forum
Hansa Biopharma AB, announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, and Maria Törnsén, COO and President US, Hansa Biopharma, participated in a fireside chat at the Virtual U.S. Bancorp / BTIG Kidney Health Forum on Wednesday October 14, 2026.
Â
🚨 The Official Guide Is Now Live!
Jefferies Global Healthcare Conference & London Life Sciences Week
London | 15-20 November 2026
The wait is over. The Official Networking Event Guide, produced by Optimum Strategic Communications and Catalyst Advisors LP in partnership with Jefferies, is now available.
The guide brings together the key receptions, workshops, panel discussions, networking events and industry gatherings taking place throughout the week, helping attendees make the most of their time in London.
🔗👉 [VIEW THE OFFICIAL NETWORKING EVENT GUIDE]
Don’t miss your chance to discover what’s happening across one of the busiest weeks in the life sciences calendar and start planning your schedule today.
🎥 Missed the conference? Catch up with the panellists’ top takeaways!
If you weren’t able to join us, or simply want to revisit some of the most insightful discussions from the day, you can now watch the Top Takeaways from the first four panel sessions on Optimum TV.
Hear directly from the speakers as they share their key insights on the issues shaping today’s life sciences sector, from financing and public markets to company building, investor engagement and future growth opportunities.
Whether you attended the event or missed it entirely, these short video round-ups are a great way to catch up on the conversations and perspectives that resonated most with delegates.
Click to Watch
Optimum’s 18th Annual Healthcare Investor Conference: AI’s role in biotech investment narratives
Optimum’s 18th Annual Healthcare Investor Conference: Public markets, what’s the point?
Optimum’s 18th Annual Healthcare Investor Conference: Fireside chat – Clive Cookson and Edith Heard
Stay tuned next week as we release the Top Takeaways from the remaining three panels.
📸 Missed our last update? The conference photos are now live!
If you haven’t had a chance to see them yet, you can now browse the event gallery, download your favourite photos and share them on social media. Don’t forget to tag Optimum so we can see your posts too.
We’d also love your feedback. If you haven’t already completed our short survey, there’s still time to have your say and help shape future events.
🔗👉 [PARTICIPATE IN THE FEEDBACK SURVEY]
🔗👉 [VIEW THE CONFERENCE PHOTO GALLERY]
👥Industry events
BIO-Europe 2026 – Cologne, Germany | 9–11th Nov 2026
Connecting with the global biotech community – Our CEO, Mary Clark, and Associate Director, Zoe Bolt, will be attending BIO-Europe 2026, one of the leading international dealmaking events for the life sciences industry.
The team are looking forward to meeting with companies, investors and potential partners to discuss collaboration opportunities. Get in touch to schedule a get-together.
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
